“ Results from ZUMA-1 Cohort 4 demonstrate that early steroid intervention has the potential to reduce the rate of severe CRS and neurologic events while appearing to maintain comparably impressive ...

Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial. Kite Pharma, a pioneer in developing the chimeric antigen receptor (CAR)-T cell treatment ...

A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting found ...

-- Unparalleled 44 Percent Estimated Four-Year Overall Survival Rate Among Refractory Large B-cell Lymphoma Patients After a Single Infusion of Yescarta -- -- Findings Support Yescarta as the First ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) today announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, ...

Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. This is an ASCO Meeting Abstract from ...